Clinical Trials

838 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03939481 2026-04-13

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

1,336 enrolled

GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms

NCT03774732 2026-02-25

NIRVANA-LUNG

327 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02153229 2025-12-26

MPM-PDT

52 enrolled

Other solid neoplasmThoracic

Epitheliod Malignant Pleural Mesothelioma

NCT07256002 2025-12-01

Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy

10,000 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

200 enrolled

Extensive Stage Small Cell Lung Cancer

NCT07215962 2025-10-14

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

300 enrolled

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07145333 2025-09-08

Drug-SNP

600 enrolled

Phase 2/3 Active not recruiting

SCLC

NCT01064466 2025-07-24

Drugs-SNPs

600 enrolled

Phase 2 Active not recruiting

Neoplasms, Small Cell Lung Carcinoma

NCT04905316 2025-06-17

CHORUS

41 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT03710876 2025-05-20

INFINITE

Other solid neoplasmThoracic

53 enrolled 23 charts

Mesothelioma, Malignant

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Phase 2 Active not recruiting

45 enrolled

Lung Neoplasms

NCT06518018 2024-07-24

HIBIC-NSCLC

80 enrolled